New england journal of medicine publishes positive phase 3 dupixent® (dupilumab) results in children with moderate-to-severe asthma

Tarrytown, n.y. and paris, dec. 8, 2021 /prnewswire/ --  dupixent significantly reduced severe asthma attacks and improved lung function and asthma control in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma published results reinforce well-established safety profile of dupixent positive data formed the basis for fda approval of dupixent in these patients with certain types of moderate-to-severe asthma and regulatory reviews are ongoing in the european union regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today announced that the new england journal of medicine has published positive results from a pivotal dupixent® (dupilumab) clinical trial in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma.
REGN Ratings Summary
REGN Quant Ranking